Eduardo Torres

US Patent:

8071581, Dec 6, 2011

Filed:

Oct 18, 2007

Appl. No.:

12/442987

Inventors:

Christopher Ronald Smith - San Diego CA, US
Pierre-Yves Bounaud - San Diego CA, US
Elizabeth Anne Jefferson - La Jolla CA, US
Patrick S. Lee - San Diego CA, US
Eduardo Torres - San Diego CA, US

Assignee:

SGX Pharmaceuticals, Inc. - San Diego CA

International Classification:

A01N 43/00

US Classification:

51421018, 435184, 514248, 514184, 514243, 544118, 544236

Abstract:

The present disclosure relates to triazolopyridazine protein kinase modulators of Formula (I), methods of using these compounds to treat diseases mediated by kinase activity.

US Patent:

8299056, Oct 30, 2012

Filed:

Sep 8, 2009

Appl. No.:

12/555018

Inventors:

Sogole Bahmanyar - San Diego CA, US
R.J. Bates - Oceanside CA, US
Kate Blease - San Diego CA, US
Andrew Calabrese - San Diego CA, US
Thomas Daniel - San Diego CA, US
Mercedes Delgado - San Diego CA, US
Jan Elsner - San Diego CA, US
Paul Erdman - San Diego CA, US
Bruce Fahr - San Diego CA, US
Gregory Ferguson - San Diego CA, US
Branden Lee - Encinitas CA, US
Lisa Nadolny - San Diego CA, US
Garrick Packard - San Diego CA, US
Patrick Papa - Carlsbad CA, US
Jennifer Riggs - Cardiff CA, US
Patricia Rohane - Florham Park NJ, US
Sabita Sankar - San Diego CA, US
John Sapienza - Chula Vista CA, US
Yoshitaka Satoh - Poway CA, US
Victor Sloan - Flemington NJ, US
Randall Stevens - Plainfield NJ, US
Lida Tehrani - San Diego CA, US
Jayashree Tikhe - San Diego CA, US
Eduardo Torres - San Diego CA, US
Andrew Wallace - San Diego CA, US
Brandon Wade Whitefield - San Diego CA, US
Jingjing Zhao - San Diego CA, US

Assignee:

Signal Pharmaceuticals, LLC - San Diego CA

International Classification:

A61K 31/437
A61K 31/5377
A61K 31/497
A61K 31/55
C07D 471/02

US Classification:

51421021, 514303, 5142332, 51425304, 51421707, 546119, 544125, 544362, 540597

Abstract:

Provided herein are Heteroaryl Compounds of formula (I):.

US Patent:

20130005707, Jan 3, 2013

Filed:

Sep 11, 2012

Appl. No.:

13/609412

Inventors:

Sogole Bahmanyar - San Diego CA, US
R.J. Bates - Oceanside CA, US
Kate Blease - San Diego CA, US
Andrew Antony Calabrese - San Diego CA, US
Thomas Oran Daniel - San Diego CA, US
Mercedes Delgado - San Diego CA, US
Jan Elsner - San Diego CA, US
Paul Erdman - San Diego CA, US
Bruce Fahr - San Diego CA, US
Gregory Ferguson - San Diego CA, US
Branden Lee - Encinitas CA, US
Lisa Nadolny - San Diego CA, US
Garrick Packard - San Diego CA, US
Patrick Papa - Carlsbad CA, US
Jennifer Riggs - Cardiff CA, US
Patricia Rohane - Florham Park NJ, US
Sabita Sankar - San Diego CA, US
John Sapienza - Chula Vista CA, US
Yoshitaka Satoh - Poway CA, US
Victor Sloan - Flemington NJ, US
Randall Stevens - Plainfield NJ, US
Lida Tehrani - San Diego CA, US
Jayashree Tikhe - San Diego CA, US
Eduardo Torres - San Diego CA, US
Andrew Wallace - San Diego CA, US
Brandon Wade Whitefield - San Diego CA, US
Jingjing Zhao - San Diego CA, US

International Classification:

A61K 31/437
A61K 31/5377
A61K 31/506
A61K 31/4545
A61K 31/496
A61K 31/551
A61P 37/00
A61P 37/08
A61P 29/00
A61P 7/02
A61P 35/00
A61P 31/00
A61P 25/28
A61P 9/00
A61P 3/00
A61P 37/06
A61P 19/02
A61P 17/00
A61P 31/12
A61P 3/10
A61P 25/00
A61P 21/04
A61P 1/00
A61P 11/02
A61P 11/00
A61P 17/06
A61P 3/04
A61P 19/06
A61P 9/10
C12N 5/071
A61K 31/4709

US Classification:

51421021, 514303, 5142332, 514256, 51425304, 514218, 51421707, 435375

Abstract:

Provided herein are Heteroaryl Compounds of formula (I):

US Patent:

20220298172, Sep 22, 2022

Filed:

May 30, 2022

Appl. No.:

17/804566

Inventors:

- San Diego CA, US
Paul E. Erdman - San Diego CA, US
Aparajita Hoskote Chourasia - San Diego CA, US
Leah M. Fung - San Diego CA, US
David Aaron Hecht - Chula Vista CA, US
Imelda Lam - San Diego CA, US
Frank Mercurio - Rancho Santa Fe CA, US
Robert W. Sullivan - Vista CA, US
Eduardo Torres - San Diego CA, US

Assignee:

BioTheryX, Inc. - San Diego CA

International Classification:

C07D 495/04
C07D 401/04
C07D 401/14

Abstract:

The present disclosure provides compounds, for example, a compound of Formula (I), that modulate a protein function and/or restore protein homeostasis. The disclosure provides a method of modulating a protein-mediated disease, disorder, condition, or response. Compositions, including in combination with other therapeutic agents, are provided.

US Patent:

20230002371, Jan 5, 2023

Filed:

Sep 14, 2020

Appl. No.:

17/753686

Inventors:

- San Diego CA, US
Aparajita Hoskote Chourasia - San Diego CA, US
Paul E. Erdman - San Diego CA, US
Leah M. Fung - San Diego CA, US
David Aaron Hecht - Chula Vista CA, US
Imelda Lam - San Diego CA, US
Frank Mercurio - Rancho Santa Fe CA, US
Robert W. Sullivan - Vista CA, US
Eduardo Torres - San Diego CA, US

International Classification:

C07D 471/04
C07D 401/14
C07D 495/04
C07D 417/14
C07D 471/14
C07D 405/14
A61P 35/00
A61P 11/00

Abstract:

Provided herein are RAS protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RAS-mediated disorder, disease, or condition.

US Patent:

20210139500, May 13, 2021

Filed:

Jan 11, 2021

Appl. No.:

17/146479

Inventors:

- San Diego CA, US
Paul E. Erdman - San Diego CA, US
Leah M. Fung - San Diego CA, US
Frank Mercurio - Rancho Santa Fe CA, US
Robert W. Sullivan - Vista CA, US
Eduardo Torres - San Diego CA, US

Assignee:

BioTheryX, Inc. - San Diego CA

International Classification:

C07D 495/04
C07D 519/00
A61P 29/00
A61P 19/02
A61P 35/00
A61P 1/00
A61P 11/00
A61P 25/28
A61P 17/06

Abstract:

The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CKα, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

US Patent:

20210128565, May 6, 2021

Filed:

Jan 12, 2021

Appl. No.:

17/147127

Inventors:

- San Diego CA, US
Sogole Bahmanyar - Rancho Santa Fe CA, US
John Frederick Boylan - Bedminster NJ, US
Joshua Hansen - La Jolla CA, US
Dehua Huang - San Diego CA, US
Robert Hubbard - San Diego CA, US
Brandon Jeffy - San Diego CA, US
Jim Leisten - San Marcos CA, US
Mehran Moghaddam - Carlsbad CA, US
Raj K. Raheja - Poway CA, US
Heather Raymon - San Diego CA, US
Kimberly Schwarz - San Diego CA, US
Marianne Sloss - San Diego CA, US
Eduardo Torres - San Diego CA, US
Tam Minh Tran - San Diego CA, US
Shuichan Xu - San Diego CA, US
JingJing Zhao - San Diego CA, US

International Classification:

A61K 31/52
C07D 473/32
A61P 35/00
A61K 31/5377

Abstract:

Provided herein are Aminopurine Compounds having the following structures:

US Patent:

20200369679, Nov 26, 2020

Filed:

May 26, 2020

Appl. No.:

16/882750

Inventors:

- San Diego CA, US
Paul E. Erdman - San Diego CA, US
Aparajita Hoskote Chourasia - San Diego CA, US
Leah Fung - San Diego CA, US
David Aaron Hecht - Chula Vista CA, US
Imelda Lam - San Diego CA, US
Frank Mercurio - Rancho Santa Fe CA, US
Robert Sullivan - Vista CA, US
Eduardo Torres - San Diego CA, US

International Classification:

C07D 495/04
C07D 401/04
C07D 401/14

Abstract:

The present disclosure provides compounds, for example, a compound of Formula (I), that modulate a protein function and/or restore protein homeostasis. The disclosure provides a method of modulating a protein-mediated disease, disorder, condition, or response. Compositions, including in combination with other therapeutic agents, are provided.